title: Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients.
abstract: Plasma homocysteine (tHcy) is an important risk factor for atherosclerosis in dialysis patients. Few data were reported on the prevalence and severity of hyperhomocysteinemia in peritoneal dialysis (PD) patients. In addition, little attention was paid to the search of factors possibly involved in the pathogenesis of hyperhomocysteinemia in these patients. A cross-sectional study was performed in 107 stable PD patients. None of them was given folate or vitamin B12 supplementation before or during the study. Plasma tHcy, serum vitamin B12, serum and erythrocyte folate were measured by immunoenzymatic methods. Genetic analysis of the methylentetrahydrofolate-reductase thermolabile mutation (tMTHFR) was performed in 61 patients. 97% of patients had tHcy levels higher than normal. tHcy was not different between men and women, patients with or without malnutrition, with or without clinically evident atherosclerotic vasculopathy, with or without anemia. tHcy levels were significantly higher in homozygotes for the tMTHFR mutation than in patients carrying the wild type form. Significant univariate correlation was found between hyperhomocysteinemia and time since the start of dialysis, serum and erythrocyte folate and vitamin B12. The best fitted model equation was log tHcy = 108.53 + 0.1606 (duration of dialysis) -1.1053 (s-F) -0.7980 (age) 0.0215 (vitamin B12). Our results agree with those reported by other authors in hemodialysis patients. Despite the large number of PD patients with normal serum vitamin B12 and folate status, the relation between tHcy and vitamin B12 or folate suggests that the supplementation of these vitamins could be useful irrespective of their serum levels, especially in younger patients or in those treated for a long period of time with peritoneal dialysis.
authors.affiliation: Divisione di Nefrologia e Dialisi, IRCCS Ospedale Maggiore, Milano, Italy. deveccpd@polic.cliea.it
authors.forename: A F
authors.initials: AF
authors.lastname: De Vecchi
authors.forename: F
authors.initials: F
authors.lastname: Bamonti-Catena
authors.forename: S
authors.initials: S
authors.lastname: Finazzi
authors.forename: C
authors.initials: C
authors.lastname: Patrosso
authors.forename: E
authors.initials: E
authors.lastname: Taioli
authors.forename: C
authors.initials: C
authors.lastname: Novembrino
authors.forename: P
authors.initials: P
authors.lastname: Colucci
authors.forename: G
authors.initials: G
authors.lastname: Lando
authors.forename: M
authors.initials: M
authors.lastname: De Franceschi
authors.forename: A
authors.initials: A
authors.lastname: Marocchi
authors.forename: A T
authors.initials: AT
authors.lastname: Maiolo
mesh_terms: D000368:Aged; D003430:Cross-Sectional Studies; D004912:Erythrocytes / Q000737:chemistry*; D005260:Female; D005492:Folic Acid / Q000097:blood*; D006710:Homocysteine / Q000097:blood*; D006720:Homozygote; D006801:Humans; D020138:Hyperhomocysteinemia / Q000175:diagnosis / Q000209:etiology / Q000235:genetics; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008875:Middle Aged; D009154:Mutation; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics; D010530:Peritoneal Dialysis / Q000009:adverse effects; D014805:Vitamin B 12 / Q000097:blood*
chemical_list: D006710:Homocysteine; D005492:Folic Acid; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D014805:Vitamin B 12